The efficacy of octreotide lar as firstline therapy for patients with newly diagnosed acromegaly is independent of tumor extension: Predictive factors of tumor and biochemical response

Hormone and Metabolic Research

Volumn 42, Issue 1, 2010, Pages 38-44

  Luque Ramirez M ^a   Portoles, G R ^b   Varela, C ^c   Albero, R ^d   Halperin, I ^e   Moreiro, J ^f   Soto, A ^g   Casamitjana, R ^e  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL RUBER INTERNACIONAL   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Acromegaly; GH; IGF 1; Somatostatin analogues

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ABDOMINAL PAIN; ACROMEGALY; ADULT; AGED; ARTICLE; BILIARY TRACT DISEASE; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GROWTH HORMONE BLOOD LEVEL; HUMAN; MALE; MICROADENOMA; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SELLA TURCICA TUMOR; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; VOMITING;

ACROMEGALY; ACTH-SECRETING PITUITARY ADENOMA; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 73949122671     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1239506     Document Type: Article

References (33)

1. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A, Acromegaly Treatment Consensus Workshop Participants. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002 87 4054-4058
2. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998 83 3419-3426
3. Freda PU, Wardlaw SL, Post KD. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998 89 353-358
4. Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G. Evolving criteria for post-operative biochemical remission of acromegaly: Can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer 2003 10 611-619
5. Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003 58 86-91
6. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G. Primary treatment of acromegaly with octreotide LAR: A long term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006 91 1397-1403
7. Cannavò S, Squadrito S, Curtò L, Almoto B, Vieni A, Trimarchi F. Results of a two-year treatment with slow release lanreotide in acromegaly. Horm Metab Res 2000 32 224-229
8. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C. Long-term effects of lanreotide SR and octreotide LAR on tumor shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002 56 65-71
9. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM. Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002 87 4554-4563
10. Grottoli S, Celleno R, Gasco V, Pivonello R, Caramella D, Barreca A, Ragazzoni F, Pigliaru F, Alberti D, Ferrara R, Angeletti G. Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: An open-label, multicenter, non-comparative study. J Endocrinol Invest 2005 28 978-983
11. Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: Results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006 64 342-351
12. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw JM, SMS995B2401 Study Group. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007 66 859-868
13. Sheaves R, Jenkins P, Blackburn P, Huneidi AH, Afshar F, Medbak S, Grossman AB, Besser GM, Wass JA. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 1996 45 407-413
14. Kreutzer J, Vance ML, Lopes MB, Laws ERJ. Surgical management of GH-secreting pituitary adenomas: An outcome study using modern remission criteria. J Clin Endocrinol Metab 2001 86 4072-4077
15. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Calì A, de Divitiis E, Lombardi G. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997 82 3308-3314
16. Abe T, Lüdecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 2001 145 137-145
17. Cannavò S, Squadrito S, Curtò L, Almoto B, Trimarchi F. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma. Horm Metab Res 2001 33 618-624
18. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J, Preoperative Octreotide Treatment of Acromegaly study group. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: A prospective, randomized trial. J Clin Endocrinol Metab 2008 93 2984-2990
19. Luque-Ramírez M, Páramo C, Varela da Costa C, García-Mayor RV. Cost of management of invasive growth hormone-secreting macroadenoma. J Endocrinol Invest 2007 30 541-545
20. Knutzen R, Ezzat S. The cost of medical care for the acromegalic patient. Neuroendocrinology 2006 83 139-144
21. Webb SM, Badia X, Surinach NL, Spanish AcroQol Study Group. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: A 6-month prospective study. Eur J Endocrinol 2006 155 269-277
22. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998 83 3034-3040
23. Gilbert J, Ketchen M, Kane P, Mason T, Baister E, Monaghan M, Barr S, Harris PE. The treatment of de novo acromegalic patients with octreotide-LAR: Efficacy, tolerability and cardiovascular effects. Pituitary 2003 6 11-18
24. Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Horm Res 2004 62 227-232
25. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: A prospective study in 99 patients. J Clin Endocrinol Metab 2006 91 2112-2118
26. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007 157 579-587
27. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Grasso LFS, Lombardi G. Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. J Clin Endocrinol Metab 2008 93 3436-3442
28. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005 153 737-740
29. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005 90 4405-4410
30. Bronstein MD. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res 2006 35 129-134
31. Lucas T, Astorga R, Catalá M, Spanish Multicentre Lanreotide Study Group on Acromegaly. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf) 2003 58 471-481
32. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004 89 667-674
33. Holdaway IM. Excess mortality in acromegaly. Horm Res 2007 68 166-172